{"id":169496,"date":"2024-06-03T02:37:28","date_gmt":"2024-06-03T06:37:28","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/alx-oncology-presents-first-evorpacept-combination-data-with-an-antibody-drug-conjugate-from-phase-1-aspen-07-clinical-trial-in-patients-with-advanced\/"},"modified":"2024-08-18T11:48:29","modified_gmt":"2024-08-18T15:48:29","slug":"alx-oncology-presents-first-evorpacept-combination-data-with-an-antibody-drug-conjugate-from-phase-1-aspen-07-clinical-trial-in-patients-with-advanced","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/alx-oncology-presents-first-evorpacept-combination-data-with-an-antibody-drug-conjugate-from-phase-1-aspen-07-clinical-trial-in-patients-with-advanced.php","title":{"rendered":"ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced&#8230;"},"content":{"rendered":"<p><![CDATA[SOUTH SAN FRANCISCO, Calif., June  02, 2024  (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (\u201cALX Oncology\u201d or \u201cthe Company\u201d) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today presented data from its Phase 1 ASPEN-07 clinical trial in a poster presentation (abstract #4575) at the 2024 American Society of Cancer Oncology (\u201cASCO\u201d) Annual Meeting being held in Chicago from May 31-June 4, 2024. These findings represent the first evorpacept combination data with an ADC from ASPEN-07\u2019s ongoing, open-label, single-arm, clinical trial of evorpacept in combination with PADCEV (enfortumab vedotin or \u201cEV\u201d) in patients with locally advanced or metastatic urothelial cancer (\u201cla\/m UC\u201d). Evorpacept is a CD47 blocker with an inactivated Fc effector domain that is designed to minimize associated toxicity.]]><\/p>\n<p>Link:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2024\/06\/02\/2891851\/0\/en\/ALX-Oncology-Presents-First-Evorpacept-Combination-Data-with-an-Antibody-Drug-Conjugate-from-Phase-1-ASPEN-07-Clinical-Trial-in-Patients-with-Advanced-Bladder-Cancer.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced...\">ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Link: ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced... <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/alx-oncology-presents-first-evorpacept-combination-data-with-an-antibody-drug-conjugate-from-phase-1-aspen-07-clinical-trial-in-patients-with-advanced.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-169496","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/169496"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=169496"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/169496\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=169496"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=169496"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=169496"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}